JANUX THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.51 USD | +0.06% |
|
-8.53% | +342.78% |
| May. 08 | Wedbush Raises Janux Therapeutics' PT to $74 From $53, Keeps Outperform Rating | MT |
| May. 08 | Janux Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 3.14M | Sales 2025 * | 2.04M | Capitalization | 2.46B |
|---|---|---|---|---|---|
| Net income 2024 * | -74M | Net income 2025 * | -97M | EV / Sales 2024 * | 784 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 1,209 x |
| P/E ratio 2024 * |
-34.6
x | P/E ratio 2025 * |
-28.1
x | Employees | 68 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.49% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | +0.06% | ||
| 1 week | -8.53% | ||
| Current month | -16.65% | ||
| 1 month | -6.01% | ||
| 3 months | +403.82% | ||
| 6 months | +438.66% | ||
| Current year | +342.78% |
1 week
46.57
51.33
1 month
44.7165.60
Current year
7.7965.60
1 year
5.6565.60
3 years
5.6565.60
5 years
5.6565.60
10 years
5.6565.60
| Managers | Title | Age | Since |
|---|---|---|---|
David Campbell
CEO | Chief Executive Officer | 65 | 17-05-31 |
Tighe Reardon
DFI | Director of Finance/CFO | 48 | 17-05-31 |
Jenna Daly
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Vickie Capps
BRD | Director/Board Member | 62 | 21-03-17 |
Jay Lichter
CHM | Chairman | 62 | 17-05-31 |
| Director/Board Member | 68 | 21-09-06 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 0 M€ | 0.00% | - | |
| 0.00% | 9 M€ | +10.70% | - | |
| 0.00% | 9 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 47.51 | +0.06% | 680,511 |
| 24-05-15 | 47.48 | -0.90% | 918,683 |
| 24-05-14 | 47.91 | -4.16% | 690,725 |
| 24-05-13 | 49.99 | +2.19% | 864,250 |
| 24-05-10 | 48.92 | -5.81% | 1,031,669 |
Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT
More quotes
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidate includes JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr), being investigated in a Phase I clinical trial in adult subjects with metastatic castration-resistant prostate cancer (mCRPC). JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Calendar
2024-06-26
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
47.51
USD
Average target price
63.57
USD
Spread / Average Target
+33.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +342.78% | 2.46B | |
| +33.37% | 49.46B | |
| +1.55% | 42.58B | |
| +49.11% | 42.49B | |
| -4.22% | 29.09B | |
| +11.57% | 26.61B | |
| -21.00% | 18.64B | |
| +7.36% | 13.16B | |
| +28.30% | 12.55B | |
| +23.80% | 12.1B |
- Stock Market
- Equities
- JANX Stock
